IN2015KN00240A - - Google Patents
Info
- Publication number
- IN2015KN00240A IN2015KN00240A IN240KON2015A IN2015KN00240A IN 2015KN00240 A IN2015KN00240 A IN 2015KN00240A IN 240KON2015 A IN240KON2015 A IN 240KON2015A IN 2015KN00240 A IN2015KN00240 A IN 2015KN00240A
- Authority
- IN
- India
- Prior art keywords
- systemic
- disorders
- diseases
- compounds
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665297P | 2012-06-27 | 2012-06-27 | |
| PCT/US2013/048274 WO2014004884A1 (fr) | 2012-06-27 | 2013-06-27 | Composés et leurs utilisations thérapeutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00240A true IN2015KN00240A (fr) | 2015-06-12 |
Family
ID=49783870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN240KON2015 IN2015KN00240A (fr) | 2012-06-27 | 2013-06-27 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150344426A1 (fr) |
| EP (1) | EP2867209A4 (fr) |
| JP (1) | JP2015522028A (fr) |
| KR (1) | KR20150024932A (fr) |
| CN (1) | CN104768931A (fr) |
| AU (1) | AU2013284487A1 (fr) |
| BR (1) | BR112014032917A2 (fr) |
| CL (1) | CL2014003560A1 (fr) |
| IL (1) | IL236499A0 (fr) |
| IN (1) | IN2015KN00240A (fr) |
| MA (1) | MA37808A1 (fr) |
| MX (1) | MX2015000101A (fr) |
| PH (1) | PH12015500179A1 (fr) |
| RU (1) | RU2015102278A (fr) |
| SG (1) | SG11201408770RA (fr) |
| WO (1) | WO2014004884A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2946130A1 (fr) | 2014-04-18 | 2015-10-22 | Millennium Pharmaceuticals, Inc. | Composes a base de quinoxaline et leurs utilisations |
| JP2017520526A (ja) * | 2014-05-22 | 2017-07-27 | ザ・ユニバーシティ・オブ・シドニー | オメガ−３類似体 |
| WO2016118565A1 (fr) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Composés quinazoline et quinoléine, et utilisations de ceux-ci |
| PT3325623T (pt) | 2015-07-23 | 2019-09-04 | Inst Curie | Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro |
| FR3047552A1 (fr) * | 2016-02-05 | 2017-08-11 | Air Liquide | Introduction optimisee d'un courant refrigerant mixte diphasique dans un procede de liquefaction de gaz naturel |
| JPWO2017170826A1 (ja) * | 2016-03-30 | 2019-02-14 | 味の素株式会社 | グルカゴン様ペプチド−１受容体作用増強活性を有する化合物 |
| KR101869794B1 (ko) * | 2016-07-20 | 2018-06-21 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
| WO2018067702A1 (fr) | 2016-10-04 | 2018-04-12 | Massachusetts Institute Of Technology | Copolymères en forme de goupillon et leurs utilisations |
| US11752221B2 (en) | 2017-06-30 | 2023-09-12 | Massachusetts Institute Of Technology | Brush-arm star polymer imaging agents and uses thereof |
| US10716858B2 (en) | 2017-06-30 | 2020-07-21 | Massachusetts Institute Of Technology | Branched multi-functional macromonomers and uses thereof |
| KR101937126B1 (ko) * | 2018-06-15 | 2019-01-10 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
| WO2020037236A1 (fr) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Polymères dégradables d'un éther de silyle cyclique et utilisations associées |
| CN114096243A (zh) * | 2018-10-22 | 2022-02-25 | 耶鲁大学 | 鉴定PPM1D突变作为NAMPTi敏感性的新型生物标志物 |
| KR20220085791A (ko) * | 2019-10-16 | 2022-06-22 | 메사추세츠 인스티튜트 오브 테크놀로지 | 브러시 전구약물 및 그의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| BR0309996A (pt) * | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias |
| AU2009286604B2 (en) * | 2008-08-29 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Novel urea and thiourea derivatives |
| CN102869261A (zh) * | 2010-03-01 | 2013-01-09 | 瑞科西有限公司 | 化合物及其治疗应用 |
| US20130273034A1 (en) * | 2010-09-03 | 2013-10-17 | Kenneth W. Bair | Novel compounds and compositions for the inhibition of nampt |
-
2013
- 2013-06-27 WO PCT/US2013/048274 patent/WO2014004884A1/fr active Application Filing
- 2013-06-27 BR BR112014032917A patent/BR112014032917A2/pt not_active IP Right Cessation
- 2013-06-27 AU AU2013284487A patent/AU2013284487A1/en not_active Abandoned
- 2013-06-27 JP JP2015520521A patent/JP2015522028A/ja active Pending
- 2013-06-27 CN CN201380045302.4A patent/CN104768931A/zh active Pending
- 2013-06-27 SG SG11201408770RA patent/SG11201408770RA/en unknown
- 2013-06-27 MX MX2015000101A patent/MX2015000101A/es unknown
- 2013-06-27 KR KR20157002268A patent/KR20150024932A/ko not_active Application Discontinuation
- 2013-06-27 EP EP13810056.5A patent/EP2867209A4/fr not_active Withdrawn
- 2013-06-27 MA MA37808A patent/MA37808A1/fr unknown
- 2013-06-27 IN IN240KON2015 patent/IN2015KN00240A/en unknown
- 2013-06-27 RU RU2015102278A patent/RU2015102278A/ru not_active Application Discontinuation
-
2014
- 2014-12-24 US US14/582,641 patent/US20150344426A1/en not_active Abandoned
- 2014-12-28 IL IL236499A patent/IL236499A0/en unknown
- 2014-12-29 CL CL2014003560A patent/CL2014003560A1/es unknown
-
2015
- 2015-01-27 PH PH12015500179A patent/PH12015500179A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104768931A (zh) | 2015-07-08 |
| AU2013284487A1 (en) | 2015-02-19 |
| BR112014032917A2 (pt) | 2017-06-27 |
| KR20150024932A (ko) | 2015-03-09 |
| US20150344426A1 (en) | 2015-12-03 |
| MX2015000101A (es) | 2015-06-22 |
| JP2015522028A (ja) | 2015-08-03 |
| SG11201408770RA (en) | 2015-01-29 |
| EP2867209A4 (fr) | 2015-11-25 |
| PH12015500179A1 (en) | 2015-04-06 |
| MA37808A1 (fr) | 2018-03-30 |
| CL2014003560A1 (es) | 2015-11-27 |
| RU2015102278A (ru) | 2016-08-20 |
| EP2867209A1 (fr) | 2015-05-06 |
| WO2014004884A1 (fr) | 2014-01-03 |
| IL236499A0 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00240A (fr) | ||
| BR112012021806A2 (pt) | compostos e seus usos terapêusticos. | |
| MX2023000079A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales. | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| WO2014160160A3 (fr) | Conjugués anticorps-médicaments | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MX2013007773A (es) | Terapia anticancer con inhibidores duales de aurora quinasa / mek. | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| NZ708727A (en) | Conjugate compounds | |
| WO2014163714A3 (fr) | Conjugués médicament-anticorps | |
| MA39934A (fr) | Variants d'anticorps anti-facteur d et leurs utilisations | |
| MX2016005446A (es) | Intervenciones a base de angiopoyetina para tratar la malaria cerebral. | |
| EP2970443A4 (fr) | Traitement anticancéreux à l'aide d'anticorps qui se lient à grp78 de surface cellulaire | |
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| MX2021006111A (es) | Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| AU2018285562A1 (en) | Dosage regimes for the administration of an anti-CD19 ADC | |
| EP3242685A4 (fr) | Molécules de liaison cxcr4 | |
| MX2019014923A (es) | Régimen de dosificación. | |
| WO2014147503A3 (fr) | Anticorps anti-bag3 utilisables à des fins thérapeutiques | |
| EP3267975A4 (fr) | Conjugués polymère-médicament pour une thérapie anticancéreuse d'association | |
| MX2016001691A (es) | Moleculas de union al receptor bag3 para uso como un medicamento. | |
| EP3452047A4 (fr) | Compositions pour le traitement de la douleur vulvaire et périnéale chronique et des symptomes et affections associés à celle-ci | |
| WO2014056779A8 (fr) | Médicament destiné à la prévention et au traitement d'une maladie neurodégénérative | |
| EP3095462A4 (fr) | Composition pharmaceutique thérapeutique utilisant un anticorps anti-slc6a6 |